Our findings suggest that, in cases of insulin-resistant GDM, the placenta does not increase IGFBP1 production sufficiently; if this association is demonstrated to be causal, this opens the door to a new therapeutic target for this GDM subtype. Here, INS is linked to gestational diabetes.